This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

This study has been terminated.
Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy
Information provided by:
Azienda Sanitaria Ospedaliera Identifier:
First received: April 18, 2006
Last updated: May 15, 2006
Last verified: January 2006
The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

Condition Intervention Phase
Coronary Disease Myocardial Infarction Drug: abciximab Phase 4

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by Azienda Sanitaria Ospedaliera:

Estimated Enrollment: 84
Study Start Date: December 2004
Estimated Study Completion Date: July 2005
Detailed Description:
Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • presenting with unstable angina
  • presenting with acute myocardial infarction
  • eligibility for percutaneous coronary intervention

Exclusion Criteria:

  • presenting with cardiogenic shock
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00320229

Cardiologia 2 - Emodinamica - Ospedale Maggiore
Novara, Italy, 28100
Sponsors and Collaborators
Azienda Sanitaria Ospedaliera
Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy
Principal Investigator: Mara Sansa Chief Interventional Cardiology - Ospedale Maggiore - Novara - Italy
  More Information Identifier: NCT00320229     History of Changes
Other Study ID Numbers: ABCX-LD
Study First Received: April 18, 2006
Last Updated: May 15, 2006

Keywords provided by Azienda Sanitaria Ospedaliera:
Platelet Glycoprotein GPIIb-IIIa Complex
myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Coronary Disease
Coronary Artery Disease
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Arterial Occlusive Diseases
Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017